Internal Medicine, Hematology & Oncology · San Jose, CA
NPI
1700930468
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
260 International Cir
San Jose, CA, 95119
Phone (408) 972-7000
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$4.1M
1,509 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Maria Pilar C Ivanov prescribed most often to Medicare patients was Anastrozole, with 437 prescriptions and refills. In total Maria Pilar C Ivanov wrote 1,509 Medicare prescriptions that cost $4.1M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-10.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Anastrozole Generic | 437 | 1,310 | 143 | $12K |
| Letrozole Generic | 159 | 475 | 62 | $3,229 |
| Dexamethasone Generic | 79 | 86 | 44 | $1,526 |
| Exemestane Generic | 79 | 207 | 30 | $5,593 |
| Ibrance Palbociclib | 64 | 64 | Under 11 | $992K |
| Ondansetron Hcl Generic | 58 | 58 | 39 | $491 |
| Tamoxifen Citrate Generic | 33 | 106 | 12 | $911 |
| Lynparza Olaparib | 32 | 32 | Under 11 | $529K |
| Famotidine Generic | 31 | 51 | 25 | $278 |
| Venclexta Venetoclax | 28 | 28 | Under 11 | $123K |
| Gabapentin Generic | 27 | 57 | 13 | $471 |
| Nivestym Filgrastim-Aafi | 27 | 27 | 13 | $24K |
| Granix Tbo-Filgrastim | 24 | 24 | Under 11 | $13K |
| Prochlorperazine Maleate Generic | 23 | 23 | 11 | $340 |
| Verzenio Abemaciclib | 22 | 22 | Under 11 | $352K |
Brand drugs: - claims; generic drugs: 1,201 claims; opioid claims: 34.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Maria Pilar C Ivanov were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.